NeurOptic
Therapy for Glaucoma
Health Tech & Life Sciences
Non Active, Apr 2018 ceased to operate
Company Overview
Snapshot
Founded in April 2017, NeurOptic operates with 1–10 employees. The company secured its Seed funding round in November 2017 from Youdim Pharmaceuticals.
Business overview
NeurOptic is a Health Tech & Life Sciences company focused on developing an ophthalmic formulation for glaucoma treatment. The company's lead product is based on an FDA-approved drug, aiming to provide sustained delivery and constant effect of a monoamine oxidase inhibitor for two months. Preliminary pre-clinical studies have indicated that this novel topical treatment can significantly impact high intraocular pressure and potentially prevent neuronal damage in the eye, serving the pharmaceutical and healthcare markets.
Company Intelligence Q&A
- What is NeurOptic's primary focus?
- NeurOptic is developing an ophthalmic formulation for the treatment of glaucoma, based on an FDA-approved drug.
- When was NeurOptic founded?
- NeurOptic was founded in April 2017.
- What is the status of NeurOptic's operations?
- NeurOptic ceased to operate in April 2018.
- What is the core technology behind NeurOptic's product?
- NeurOptic's product utilizes a monoamine oxidase inhibitor in an ophthalmic formulation designed for prolonged residence time on the ocular surface, providing sustained drug delivery for two months.